Recombinant DNA Technology Market Research Report - Forecast to 2027

Recombinant DNA Technology Market Research Report: By Product (Medical, Non-Medical), Component (Expression System, Cloning Vector), Application (Food & Agriculture, Health & Disease), End-User (Biotechnology Companies, Pharmaceuticals) – Forecast to 2027

ID: MRFR/LS/4389-HCR | February 2021 | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


The recombinant DNA technology is a process that manipulates and alters the DNA sequences, resulting in a genetically modified organism and product. These genetically modified products or organisms have superior or specific ability such as resistance to certain chemicals, high productivity, and survival abilities in harsh conditions (GM crops).


The recombinant DNA technology has a practical application of biotechnology in the fields of applied immunology, genomics, diagnostic tools, and development of pharmaceutical therapeutics. There are numerous biological methods used to create a recombinant DNA. The treatment was developed for leukemia disorder, in conjugation between the Novartis Corp and the University of Pennsylvania.


Factors such as the commercial success of the recombinant DNA technology in the biopharmaceutical industry, the increasing adoption of genetically modified crops and biopesticides, and the increasing burden of chronic diseases are driving the growth of the market. Moreover, the increasing need to improve the recombinant protein production capacity and the presence of robust biopharmaceuticals pipeline are increasing the demand for effective therapeutics for disease treatment.


Presently, the genetic testing market is majorly spread in Western Europe and North American. There are vast opportunities for the companies and service providers to make the tests affordable and enter the untapped regions of the world with a great scope of expanding.


The global recombinant DNA technology market is expected to grow at a CAGR of approximately 6.9% during the forecast period, 2017–2023.


Intended Audience



  • Recombinant DNA Technology Test Kit Suppliers

  • Recombinant DNA Technology Test Kit Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Figure 1: - Global Recombinant DNA Technology Market Share, by Region


 Recombinant DNA Technology Market Share


Segmentation                                                                                                


The global recombinant DNA technology market is segmented on the basis of product, component, application, and end-user.


On the basis of product, the global recombinant DNA technology market is segmented into medical, non-medical, and others. The medical segment is divided into therapeutic agents, human proteins, and vaccines. The non-medical segment is divided into biotech crops, specialty chemicals, and others.


On the basis of component, the global recombinant DNA technology market is segmented into expression system, cloning vector, and others. The expression system segment is divided into mammalian, bacteria, yeast, baculovirus/insect, and others. The cloning vector segment is divided into plasmid, phage, cosmid, Bacterial Artificial Chromosome (BAC), Yeast Artificial Chromosome (YAC), and Human Artificial Chromosome (HAC).


On the basis of application, the global recombinant DNA technology market is segmented into food and agriculture, health and disease, environment, and others.


On the basis of end-user, the global recombinant DNA technology market is segmented into biotechnology companies, academic and government research institutes, pharmaceuticals, and others.


Research Methodology


 Recombinant DNA Technology Market Methodology


Sources: Annual reports, Press release, White paper, and Company presentation


Regional Analysis


The global recombinant DNA technology market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.


The Americas contributes a major share to the recombinant DNA technology market owing to the widespread successful applications of this technique in veterinary products’ development, genetically modified crops’ development, biopesticides’ and biofuels’ production, and gene therapy. All these factors are expected to spur the adoption of this technology throughout the forecast period.


The European market holds the second largest share of the global recombinant DNA technology market owing to the increasing investments by hospital facilities and by the government for better healthcare. The growing collaborations and partnerships, the low cost of sequencing, and the increasing adoption of NGS procedure by research laboratories are driving the growth of this market.


The Asia Pacific region is expected to witness a rapid growth rate over the forecast period. Countries such as India and China are expected to support the growth of Asia Pacific owing to the increasing government funding for research and development. Moreover, conducting clinical trials in Asian countries such as India are relatively less costly in comparison with the western countries. This has resulted in the migration of several global biopharmaceutical developers towards this region.


The Middle East and Africa are also expected to show healthy growth in the coming five years. There are some factors affecting the growth of the recombinant DNA technology in the Middle East such as lack of knowledge of genetic diseases and disorders, weak health care and research infrastructure, traditional healthcare practices, limited availability of products and services, and cost of the tests.


Key Players


Some of the key players in the global recombinant DNA technology market are F. Hoffmann-La Roche Ltd (Switzerland), Profacgen (U.S.), Amgen Inc. (U.S.), Novartis AG (Switzerland), Genscript Biotech (U.S.), Pfizer Inc. (U.S.), Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Sanofi S.A. (France), Merck & Co., Inc. (U.S.), Biogen Inc. (U.S.), Biocon Limited (India), GlaxoSmithKline plc (UK), New England Biolabs (U.S.), Cibus (U.S.), Monsanto Company (U.S.), Horizon Discovery Group PLC (U.S.), Boehringer Ingelheim (Germany), and others.



Frequently Asked Questions (FAQ) :


Recombinant DNA technology is a process that manipulates and alters the DNA sequences, resulting in a genetically modified organism.

Recombinant DNA Technology Market is expected to exhibit a strong 6.9% CAGR over the forecast period from 2017 to 2023.

Growing demand for recombinant DNA technology in therapeutic applications is a major driver for the market.

Americas hold the dominant share in the global Recombinant DNA Technology Market.

Leading players in the Recombinant DNA Technology Market include Novartis, Profacgen, and Amgen, among others.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Recombinant DNA Technology Market, by Product

6.1 Introduction

6.2 Medical

6.2.1 Market Estimates & Forecast, 2020-2027

6.2.2 Therapeutic Agent

6.2.2.1 Market Estimates & Forecast, 2020-2027

6.2.3 Human Protein

6.2.3.1 Market Estimates & Forecast, 2020-2027

6.2.4 Vaccine

6.2.4.1 Market Estimates & Forecast, 2020-2027

6.3 Non-Medical

6.3.1 Market Estimates & Forecast, 2020-2027

6.3.2 Biotech Crops

6.3.2.1 Market Estimates & Forecast, 2020-2027

6.3.3 Specialty Chemicals

6.3.3.1 Market Estimates & Forecast, 2020-2027

6.3.4 Others

6.3.4.1 Market Estimates & Forecast, 2020-2027

6.4 Others

Chapter 7. Global Recombinant DNA Technology Market, by Component

7.1 Introduction

7.2 Expression System

7.2.1 Market Estimates & Forecast, 2020-2027

7.2.2 Mammalian

7.2.2.1 Market Estimates & Forecast, 2020-2027

7.2.3 Bacteria

7.2.3.1 Market Estimates & Forecast, 2020-2027

7.2.4 Yeast

7.2.4.1 Market Estimates & Forecast, 2020-2027

7.2.4 BaculovirU.S./Insect

7.2.4.1 Market Estimates & Forecast, 2020-2027

7.2.5 Others

7.2.5.1 Market Estimates & Forecast, 2020-2027

7.3 Cloning Vector

7.3.1 Market Estimates & Forecast, 2020-2027

7.3.2 Plasmid

7.3.2.1 Market Estimates & Forecast, 2020-2027

7.3.3 Phage

7.3.3.1 Market Estimates & Forecast, 2020-2027

7.3.4 Cosmid

7.3.4.1 Market Estimates & Forecast, 2020-2027

7.3.5 Bacterial Artificial Chromosome (BAC)

7.3.5.1 Market Estimates & Forecast, 2020-2027

7.3.6 Yeast Artificial Chromosome (YAC)

7.3.6.1 Market Estimates & Forecast, 2020-2027

7.3.7 Human Artificial Chromosome (HAC).

7.3.7.1 Market Estimates & Forecast, 2020-2027

7.4 Others

Chapter 8. Global Recombinant DNA Technology Market, by Application

8.1 Introduction

8.2 Food & Agriculture

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Health & Disease

8.3.1 Market Estimates & Forecast, 2020-2027

8.4 Environment

8.4.1 Market Estimates & Forecast, 2020-2027

8.5 Others

Chapter 9. Global Recombinant DNA Technology Market, by End-U.S.er

9.1 Introduction

9.2 Biotechnology Companies

9.2.1 Market Estimates & Forecast, 2020-2027

9.3 Academic & Government Research Institutes

9.3.1 Market Estimates & Forecast, 2020-2027

9.4 Pharmaceuticals

9.4.1 Market Estimates & Forecast, 2020-2027

9.5 Others

Chapter .8 Global Recombinant DNA Technology Market, by Region

8.1 Introduction

8.2 Americas

8.2.1 North America

8.2.1.1 U.S.

8.2.1.1 Canada

8.2.2 South America

8.3 Europe

8.3.1 Western Europe

8.3.1.1 Germany

8.3.1.2 France

8.3.1.3 Italy

8.3.1.4 Spain

8.3.1.5 U.K.

8.3.1.6 Rest of Western Europe

8.3.2 Eastern Europe

8.4 Asia Pacific

8.4.1 Japan

8.4.2 China

8.4.3 India

8.4.4 Australia

8.4.5 Republic of Korea

8.4.6 Rest of Asia Pacific

8.5 The Middle East & Africa

8.5.1 United Arab Emirates

8.5.2 Saudi Arabia

8.5.3 Oman

8.5.4 Kuwait

8.5.5 Qatar

8.5.6 Rest of the Middle East & Africa

Chapter 9 Company Landscape

9.1 Introduction

9.2 Market Share Analysis

9.3 Key Development & Strategies

9.3.1 Key Developments

Chapter 10 Company Profiles

10.1 F. Hoffmann-La Roche Ltd

10.1.1 Company Overview

10.1.2 Product Overview

10.1.3 Financials

10.1.4 SWOT Analysis

10.2 Profacgen

10.2.1 Company Overview

10.2.2 Product Overview

10.2.3 Financial Overview

10.2.4 Key Developments

10.2.5 SWOT Analysis

10.3 Amgen Inc.

10.3.1 Company Overview

10.3.2 Product Overview

10.3.3 Financial Overview

10.3.4 Key Development

10.3.5 SWOT Analysis

10.4 Novartis AG

10.4.1 Company Overview

10.4.2 Product/Business Segment Overview

10.4.3 Financial Overview

10.4.4 Key Development

10.4.5 SWOT Analysis

10.5 Genscript Biotech

10.5.1 Company Overview

10.5.2 Product Overview

10.5.3 Financial overview

10.5.4 Key Developments

10.6 Pfizer Inc.

10.6.1 Company Overview

10.6.2 Product Overview

10.6.3 Financial Overview

10.6.4 Key Developments

10.7 Novo Nordisk A/S

10.7.1 Overview

10.7.2 Product Overview

10.7.3 Financials

10.7.4 Key Developments

10.7.5 SWOT Analysis

10.8 Eli Lilly and Company

10.8.1 Company Overview

10.8.2 Product/Business Segment Overview

10.8.3 Financial Overview

10.8.4 Key Development

10.8.5 SWOT Analysis

10.9 Sanofi S.A.

10.9.1 Company Overview

10.9.2 Product Overview

10.9.3 Financial overview

10.9.4 Key Developments

10.10 Merck & Co., Inc.

10.10.1 Company Overview

10.10.2 Product Overview

10.10.3 Financial overview

10.10.4 Key Developments

10.11 Biogen Inc.

10.11.1 Company Overview

10.11.2 Product Overview

10.11.3 Financial overview

10.11.4 Key Developments

10.12 Others

Chapter 17 MRFR Conclusion

11.1 Key Findings

11.1.1 From CEO’s View Point

11.1.2 Unmet Needs of the Market

11.2 Key Companies to Watch

11.3 Prediction of the Pharmaceutical Industry

Chapter 12 Appendix

LIST OF TABLES

Table 1 Recombinant DNA technology Industry Synopsis, 2020-2027

Table 2 Recombinant DNA Technology Market Estimates & Forecast, 2020-2027, (USD Million)

Table 3 Recombinant DNA Technology Market, by Region, 2020-2027, (USD Million)

Table 4 Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 5 Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 6 Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 7 Recombinant DNA Technology Market, by End-U.S.er, 2020-2027, (USD Million)

Table 8 North America Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 9 North America Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 10 North America Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 11 North America Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 12 U.S. Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 13 U.S. Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 14 U.S. Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 15 U.S. Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 16 Canada Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 17 Canada Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 18 Canada Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 19 Canada Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 20 South America Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 21 South America Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 22 South America Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 23 South America Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 24 Europe Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 25 Europe Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 26 Europe Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 27 Europe Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 28 Western Europe Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 29 Western Europe Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 30 Western Europe Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 31 Western Europe Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 32 Eastern Europe Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 33 Eastern Europe Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 34 Eastern Europe Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 35 Eastern Europe Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 36 Asia Pacific Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 37 Asia Pacific Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 38 Asia Pacific Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 39 Asia Pacific Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

Table 40 The Middle East & Africa Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)

Table 41 The Middle East & Africa Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)

Table 42 The Middle East & Africa Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)

Table 43 The Middle East & Africa Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation of the Recombinant DNA Technology Market

Figure 3 Segmentation Market Dynamics for the Recombinant DNA Technology Market

Figure 4 Global Recombinant DNA Technology Market Share, by Product 2020

Figure 5 Global Recombinant DNA Technology Market Share, by Component 2020

Figure 6 Global Recombinant DNA Technology Market Share, by Application 2020

Figure 7 Global Recombinant DNA Technology Market Share, by End-User2020

Figure 8 Global Recombinant DNA Technology Market Share, by Region, 2020

Figure 9 Americas Recombinant DNA Technology Market Share, by Country, 2020

Figure 10 Europe Recombinant DNA Technology Market Share, by Country, 2020

Figure 11 Asia Pacific Recombinant DNA Technology Market Share, by Country, 2020

Figure 12 Middle East & Africa Recombinant DNA Technology Market Share, by Country, 2020

Figure 13 Global Recombinant DNA Technology Market: Company Share Analysis, 2020 (%)

Figure 14 F. Hoffmann-La Roche Ltd: Key Financials

Figure 15 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 16 F. Hoffmann-La Roche Ltd: Geographical Revenue

Figure 17 Profacgen: Key Financials

Figure 18 Profacgen: Segmental Revenue

Figure 19 Profacgen: Geographical Revenue

Figure 20 Amgen Inc.: Key Financials

Figure 21 Amgen Inc.: Segmental Revenue

Figure 22 Amgen Inc.: Geographical Revenue

Figure 23 Novartis AG: Key Financials

Figure 24 Novartis AG: Segmental Revenue

Figure 25 Novartis AG: Geographical Revenue

Figure 26 Genscript Biotech: Key Financials

Figure 27 Genscript Biotech: Segmental Revenue

Figure 28 Genscript Biotech: Geographical Revenue

Figure 29 Pfizer Inc.: Key Financials

Figure 30 Pfizer Inc.: Segmental Revenue

Figure 31 Pfizer Inc.: Geographical Revenue

Figure 32 Novo Nordisk A/S: Key Financials

Figure 33 Novo Nordisk A/S: Segmental Revenue

Figure 34 Novo Nordisk A/S: Geographical Revenue

Figure 35 Eli Lilly and Company: Key Financials

Figure 36 Eli Lilly and Company: Segmental Revenue

Figure 37 Eli Lilly and Company: Geographical Revenue